Jongmyung Kim, MD, PhD

Cancer Focus:
Lung Cancer, Mesothelioma, Pancoast Tumor, Thymoma

Dr. Jongmyung Kim is a board-certified radiation oncologist specializing in the treatment, management, and prevention of primary and metastatic lung cancers. He is an Assistant Member in the Departments of Radiation Oncology and Immunology at Moffitt Cancer Center and an Assistant Professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. His expertise spans delivering high-quality patient care and advancing innovative theranostic strategies to overcome therapeutic resistance, with the goal of improving outcomes for patients with advanced or treatment-refractory lung cancers. Dr. Kim’s clinical approach emphasizes holistic, patient-centered care that addresses both the physical and emotional needs of his patients.

Dr. Kim’s career is marked by his service as a Sergeant in the 8th U.S. Army through the KATUSA (Korean Augmentation to the United States Army) program, where he was honored with U.S. Army Achievement Medals in 2003 and 2004. He earned his MD-PhD from Pusan National University School of Medicine. After completing the Medical Scientist Training Program, Dr. Kim pursued postdoctoral research on cancer stem cells at the Cleveland Clinic (Cleveland, OH), Moffitt Cancer Center (Tampa, FL), and Rutgers Cancer Institute of New Jersey (New Brunswick, NJ). He went on to complete a surgical internship at the University of Louisville (Louisville, KY), followed by a Radiation Oncology residency at Rutgers Cancer Institute of New Jersey/Rutgers Robert Wood Johnson Medical School, where he served as Chief Resident.

Dr. Kim’s research focuses on developing and translating novel theranostic strategies to overcome therapeutic resistance in primary and metastatic lung cancer. He employs phage display technologies to identify and engineer tumor-specific peptides for peptide-directed immuno-radiotherapy, radiopharmaceuticals, and bispecific antibody platforms designed to enhance tumor targeting and immune modulation. In parallel, his work investigates radiation-guided immune modulation as a synergistic approach to amplify anti-tumor immunity and sensitize resistant cancers to therapy. Ultimately, Dr. Kim integrates these strategies into clinical trials aimed at overcoming therapeutic resistance and advancing patient-centered care. His research has been published in high-impact journals, including Cancer Cell, Science Translational Medicine, and Stem Cells. 

Nationally, Dr. Kim serves on the Education Committee of the American Society for Radiation Oncology (ASTRO). He is also a member of the Scientific Review Committee at Moffitt Cancer Center. In addition to his clinical and research efforts, he is committed to mentoring future healthcare professionals and serves as Director of the Resident Radiation Biology Course. Dr. Kim’s contributions to oncology have been recognized by multiple professional societies. He is the recipient of several prestigious honors, including the 2023 American Society for Radiation Oncology (ASTRO) Recognition Award, the 2023 Korean American Society for Radiation Oncology (KASTRO) Research Grant Award, and the 2022 Radiological Society of North America (RSNA) Roentgen Resident/Fellow Research Award.

 

Education & Training

Board Certification:

• Radiation Oncology -

Fellowship:

• Moffitt Cancer Center (Tampa, FL) - Department of Neuro-Oncology (Cancer Stem Cell Biology)
• Cleveland Clinic (Cleveland, OH) - Department of Stem Cell Biology (Cancer Stem Cell Biology)
• Rutgers Cancer Institute of New Jersey (New Brunswick, NJ) - Section of Urologic Oncology (Cancer Cell Biology)

Residency:

• Rutgers Cancer Institute of New Jersey (New Brunswick, NJ) - Radiation Oncology (Residency)
• University of Louisville School of Medicine (Louisville, KY) - General Surgery (Internship)

Medical School:

• Pusan National University School of Medicine (South Korea) - MD/PhD

• Deek RA, Kim J, Kumar R, Medina B, Langenfeld J, Kontopidis I, Lazzaro R, Nie K, Hathout L, Guler O, Onal C, Patel E, Haigentz M, Jabbour SK, Deek MP. Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer. Clin Lung Cancer. 2025 Nov.26(7):e609-e615.e11. Pubmedid: 40897601.
• Cruz-Chamorro R, Bryant JM, Henning J, Robinson LA, Lee DH, Fontaine J, Toloza E, Rosenberg SA, Kim J, Naqa IE, Dilling TJ. Factors impacting cardiac dose and overall survival in post-operative non-small cell lung cancer patients. Radiother Oncol. 2025 Nov.212:111117. Pubmedid: 40854381.
• Chafe SC, Zhai K, Aghaei N, Miletic P, Huang Z, Brown KR, Mobilio D, Young D, Suk Y, Grewal S, McKenna D, Alizada Z, Kieliszek AM, Lam FC, Escudero L, Huang Q, Huebner A, Lu J, Ang P, Anand A, Custers S, Apel E, Slassi S, Brakel B, Kim J, Liu JKC, Bassey-Archibong BI, Abdo R, Shargall Y, Lu JQ, Cutz JC, Zhang Q, Li SS, Venugopal C, Hynds RE, Dufour A, Moffat J, Swanton C, Bao S, Singh SK. A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis. Sci Transl Med. 2025 Jul.17(805):eadu2459. Pubmedid: 40601773. Pmcid: PMC7617989.
• Sutera P, Kim J, Kumar R, Deek RA, Stephenson R, Mayer T, Saraiya B, Ghodoussipour S, Jang T, Golombos D, Packiam V, Ennis R, Hathout L, Jabbour SK, Guler O, Onal C, Tran PT, Deek MP. PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer. Prostate. 2024 Oct.84(14):1301-1308. Pubmedid: 39021052.
• Wang T, Kim J, Kumar R, Deek RA, Stephenson R, Mayer T, Saraiya B, Ghodoussipour S, Jang T, Golombos D, Packiam V, Ennis R, Hathout L, Jabbour SK, Guler O, Onal C, Deek MP. Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer. Transl Cancer Res. 2024 Nov.13(11):6235-6245. Pubmedid: 39697761. Pmcid: PMC11651787.
• Kim J, Fahmy V, Haffty BG. Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives. Expert Rev Anticancer Ther. 2024 May.24(5):211-217. Pubmedid: 38502143.
• Huang Q, Liu L, Xiao D, Huang Z, Wang W, Zhai K, Fang X, Kim J, Liu J, Liang W, He J, Bao S. CD44+ lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration. Cancer Cell. 2023 Sep.41(9):1621-1636.e8. Pubmedid: 37595587.
• Kim J, Haffty BG. Genetic Factors in the Screening and Imaging for Breast Cancer. Korean J Radiol. 2023 May.24(5):378-383. Pubmedid: 37056158. Pmcid: PMC10157325.
• Potez M, Snedal S, She C, Kim J, Thorner K, Tran TH, Ramello MC, Abate-Daga D, Liu JKC. Use of phage display biopanning as a tool to design CAR-T cells against glioma stem cells. Front Oncol. 2023 Mar.13:1124272. Pubmedid: 37035164. Pmcid: PMC10080078.
• Kim J, Mukherji S, Haigentz M, Stubbs VC, Kim S. A rare pattern of local recurrence in the nasopharyngeal carcinoma: Case report. Otolaryngol Case Rep. 2023 Jun.27.
• Kumar R, Kim J, Deek MP, Eskander MF, Gulhati P, In H, Kennedy T, Shah MM, Grandhi MS, Berim L, Spencer KR, Langan RC, Hochster HS, Boland PM, Jabbour SK. Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research. Curr Oncol. 2023 Jul.30(7):6432-6446. Pubmedid: 37504333. Pmcid: PMC10378032.
• Kim J, Potez M, She C, Huang P, Wu Q, Bao S, Rich JN, Liu JKC. Glioblastoma Stem Cell Targeting Peptide Isolated Through Phage Display Binds Cadherin 2. Stem Cells. 2023 Aug.41(8):762-774. Pubmedid: 37280108. Pmcid: PMC10427963.
• Kim J, She C, Potez M, Huang P, Wu Q, Prager BC, Qiu Z, Bao S, Rich JN, Liu JKC. Phage display targeting identifies EYA1 as a regulator of glioblastoma stem cell maintenance and proliferation. Stem Cells. 2021 Jul.39(7):853-865. Pubmedid: 33594762. Pmcid: PMC10741052.
• Lee GT, Kwon SJ, Kim J, Kwon YS, Lee N, Hong JH, Jamieson C, Kim WJ, Kim IY. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. Brit J Cancer. 2018 Mar.118(5):670-678. Pubmedid: 29381686. Pmcid: PMC5846063.
• Yu J, Kwon YS, Kim S, Han CS, Farber N, Kim J, Byun SS, Kim WJ, Jeon SS, Kim IY. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. J Urol. 2016 May.195(5):1464-1470. Pubmedid: 26608903. Pmcid: PMC5769700.
• Kim JM, Cho HH, Lee SY, Hong CP, Yang Jw, Kim YS, Suh KT, Jung JS. Role of IRAK1 on TNF-induced proliferation and NF-ĸB activation in human bone marrow mesenchymal stem cells. Cell Physiol Biochem. 2012 Oct.30(1):49-60. Pubmedid: 22759955.
• Kim JM, Yu JM, Bae YC, Jung JS. Analysis of Global Gene Expression Profile of Human Adipose Tissue Derived Mesenchymal Stem Cell Cultured with Cancer Cells. Saengmyeong gwahag hoeji. 2011 May.21(5):631-646.
• Kim JM, Song JS, Cho HH, Shin KK, Bae YC, Lee BJ, Jung JS. Effect of the modulation of leucine zipper tumor suppressor 2 expression on proliferation of various cancer cells functions as a tumor suppressor. Mol Cell Biochem. 2011 Jan.346(1-2):125-136. Pubmedid: 20890637.
• Cho HH, Shin KK, Kim YJ, Song JS, Kim JM, Bae YC, Kim CD, Jung JS. NF-kappaB activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression. J Cell Physiol. 2010 Apr.223(1):168-177. Pubmedid: 20049872.

2023 ASTRO Annual Meeting Recognition Award (Biology), American Society for Radiation Oncology

2023 KASTRO Robert Y. Kim MD Annual U.S. Resident/Fellow Research Grant Award, Korean American Society for Radiation Oncology

2022 RSNA Roentgen Fellow/Resident Research Award, Radiological Society of North America